Terms: = Lymphoma AND TNFAIP3, TNFA1P2, 7128, ENSG00000118503, OTUD7C, MGC138687, MGC104522, A20, MGC138688, P21580 AND Treatment
95 results:
1. Primary central nervous system marginal zone lymphoma.
Flospergher E; Marino F; Calimeri T; Cangi MG; Ferreri AJM; Ponzoni M; Bongiovanni L
Br J Haematol; 2024 Jan; 204(1):31-44. PubMed ID: 38054330
[TBL] [Abstract] [Full Text] [Related]
2. A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease.
Sun W; Zheng J; Zhou J; Zhou J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 52(5):583-587. PubMed ID: 37899398
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathologic and mutational profiles of primary breast diffuse large B cell lymphoma in a male patient: case report and literature review.
Huang F; Ruan Y; He X; Lian H; Yang J
World J Surg Oncol; 2023 Oct; 21(1):342. PubMed ID: 37884941
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement.
Geng H; Jia S; Zhang Y; Li J; Yang Q; Zeng L; Zong X; Lu Y; Lu S; Zhou J; Li C; Wu D
Front Immunol; 2023; 14():1219167. PubMed ID: 37671152
[TBL] [Abstract] [Full Text] [Related]
5. Identification of a novel RSRC1-ALK (R6: a20) fusion using next-generation sequencing technique.
Xia J; Chen S; Zhang Z; Wang J
Cancer Genet; 2023 Nov; 278-279():18-23. PubMed ID: 37572583
[TBL] [Abstract] [Full Text] [Related]
6. [Ceritinib as First-line treatment for Advanced Lung Adenocarcinoma
with COX7A2L-ALK Fusion: A Case Report and Literature Review].
Yuan J; Pan R; Zhong W; Wang M
Zhongguo Fei Ai Za Zhi; 2023 Apr; 26(4):319-324. PubMed ID: 37183647
[TBL] [Abstract] [Full Text] [Related]
7. Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.
Tatarczuch M; Waltham M; Shortt J; Polekhina G; Hawkes EA; Ho SJ; Trotman J; Brasacchio D; Co M; Li J; Ramakrishnan V; Dunne K; Opat SS; Gregory GP
Blood Adv; 2023 Jul; 7(14):3531-3539. PubMed ID: 36947202
[TBL] [Abstract] [Full Text] [Related]
8. Targeting CD47 enhanced the antitumor immunity of PD-L1 blockade in B-cell lymphoma.
Nan Y; Zhang X; Wang S; Xu C; Wang Y; Han L; Luan J; Hu X; Chen W; Cao Z; Zhu Z; Zeng X; Fan J; Ye L; Shi X; Ju D
Immunotherapy; 2023 Feb; 15(3):175-187. PubMed ID: 36727256
[TBL] [Abstract] [Full Text] [Related]
9. Frequent Gene Mutations and Their Possible Roles in the Pathogenesis, treatment and Prognosis of Primary Central Nervous System lymphoma.
Jin Q; Jiang H; Han Y; Li C; Zhang L; Zhang Y; Chai Y; Zeng P; Yue L; Wu C
World Neurosurg; 2023 Feb; 170():99-106. PubMed ID: 36396049
[TBL] [Abstract] [Full Text] [Related]
10. Transformation of FL into DLBCL with a PMBL gene expression signature.
Loveday T; Duns G; Rimsza LM; Rech KL; Cook JR; Robetorye RS; Rosenthal AC; Ramsower CA; Yip TK; McKinney CL; Swerdlow SH; Bhavsar S; Steidl C; Gibson SE
Blood Adv; 2023 Mar; 7(6):893-899. PubMed ID: 36240289
[TBL] [Abstract] [Full Text] [Related]
11. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
Guo W; Liang J; Zhang D; Huang X; Lv Y
Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
[TBL] [Abstract] [Full Text] [Related]
12. Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer.
Ding Y; Sun C; Su W; Miao C; He X; Wang JS; Zhang ZH
Virchows Arch; 2022 Sep; 481(3):405-419. PubMed ID: 35624360
[TBL] [Abstract] [Full Text] [Related]
13.
Fan L; Liao W; Chen Z; Li S; Yang A; Chen MM; Liu H; Liu F
Aging (Albany NY); 2022 May; 14(9):3801-3812. PubMed ID: 35504024
[TBL] [Abstract] [Full Text] [Related]
14. The physical exam's role in determining dose-limiting toxicity prior to immunochemotherapy administration in lymphoma.
Runge JS; Brown AB; Phillips TJ; Kaminski MS; Carty SA; Wilcox RA
J Oncol Pharm Pract; 2023 Apr; 29(3):601-602. PubMed ID: 35105218
[TBL] [Abstract] [Full Text] [Related]
15. Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.
Kang J; Deng QM; Peng KC; Li P; Zhu BT; Wang P; Chu XP; Zhong WZ; Chen HJ; Wang WX; Chen HF; Rao CZ; Xu CW; Yang JJ
Genes Chromosomes Cancer; 2022 Apr; 61(4):177-186. PubMed ID: 34687488
[TBL] [Abstract] [Full Text] [Related]
16. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H
Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256
[TBL] [Abstract] [Full Text] [Related]
17. Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin.
Vela V; Juskevicius D; Dirnhofer S; Menter T; Tzankov A
Virchows Arch; 2022 Feb; 480(2):403-413. PubMed ID: 34494161
[TBL] [Abstract] [Full Text] [Related]
18. The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
Bissonnette RP; Cesario RM; Goodenow B; Shojaei F; Gillings M
BMC Cancer; 2021 Aug; 21(1):969. PubMed ID: 34461854
[TBL] [Abstract] [Full Text] [Related]
19. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W
Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
[TBL] [Abstract] [Full Text] [Related]
20. Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Ashraf U; Ding Z; Deng S; Ye J; Cao S; Chen Z
Virulence; 2021 Dec; 12(1):968-980. PubMed ID: 33724154
[TBL] [Abstract] [Full Text] [Related]
[Next]
